Business Wire

CO-LIQID-INC.

22.6.2022 17:32:06 CEST | Business Wire | Press release

Share
Case Study: Durham University Deploys Liqid Composable Infrastructure to Study Universe’s 14 Billion-Year History with Adaptive, More Sustainable Infrastructure

LIQID Inc., one of the world’s leading software companies delivering data center composability, announced today a new case study with Durham University in Durham, England, describing its deployment of Liqid composable disaggregated infrastructure (CDI) software. Durham University is home to the COSmology MAchine (COSMA) operated by the Institute for Computational Cosmology (ICC) and is a national supercomputing facility that is part of the UK’s Distributed Research utilizing Advanced Computing (DiRAC) system. Liqid Matrix™ CDI software is part of a system used to study the origins of the universe, composing disaggregated GPUs in a tight footprint designed for a more sustainable digital architecture. With the ability to grow as resources are needed, the Liqid system will help researchers in the UK and around the world unlock the mysteries of the 14 billion-year history of the cosmos with far greater speed and efficiency than traditional data center systems.

“We are honored to work with institutions like Durham University and COSMA researchers to provide the resources to better explore the most profound questions in science,” said Sumit Puri, CEO & Cofounder, Liqid. “By providing the kind of software-defined data performance and architectural flexibility for powerful GPU, Liqid is enabling research breakthroughs that would have been impossible with traditional, static data center architectures so scientists can focus on results instead of waiting for resources and performance to become available.”

Liqid Matrix CDI Delivers Big Bang for Cosmologists with Adaptive, Efficient Architecture

“Durham University is using cutting-edge CDI to accelerate research, improve resource utilization, and reduce the university’s carbon footprint,” said Alistair Basden, technical manager for the DiRAC Memory Intensive Service at Durham University, who was interviewed for the case study entitled Durham University’s Institute for Computational Cosmology Accelerates Results with Composability from Liqid .

The COSMA memory-intensive system is designed specifically to support the largest cosmological simulations, most notably running simulations starting with the Big Bang and propagating through the entire history of the universe. Each simulation of dark matter, dark energy, black holes, galaxies and other structures in the universe often takes months to run, followed by long periods of data analysis.

While all of the applications deployed by DiRAC are memory intensive, valuable GPU resources are required for some of its most challenging simulations and analysis. Durham University chose Liqid Matrix software-based composable system in order to be able to share and scale GPUs in the exact amounts required for any given workload. Once the workload has been completed, GPU resources can be redistributed through Liqid Matrix software for use by other applications.

“It would be wasteful for us to populate all our nodes with GPUs,” Basden said in an interview for the case study. “Instead, we have some fat compute nodes and a login node, and we’re able to move GPUs between those systems. Composing our GPUs gives us flexibility with a smaller number of GPUs. We can individually populate the servers with one or more GPUs as required at the click of a button.”

Durham University IT is also deploying Liqid Matrix-based systems as an element of its overall strategy for a more sustainable IT ecosystem. Software-based composability enables users to do more with less, increasing efficiency and curtailing the need for physical space to store the hardware while providing significant reductions in cooling and water requirements.

“Rather than populating all our servers with GPUs, we can compose the resources we need to each server. That reduces our carbon footprint,” said Basden.

To learn more about Liqid’s academic deployments, review Liqid’s case study outlining the company’s work with the University of Illinois at Chicago’s Electronic Visualization Laboratory . Schedule an appointment with an expert on solutions based on Liqid Matrix ™ CDI software-based and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.

About Liqid Inc.

Liqid’s composable infrastructure software platform, Liqid Matrix ™, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT professionals can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.

Social Media:

https://www.facebook.com/WeAreLiqid/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye